Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gruben

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Contemporary Clinical Trials|May 3, 2021
Demographic diversity of participants in Pfizer sponsored clinical trials in the United StatesMelinda Rottas, Peter Thadeio, Rachel Simons, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 31, 2025
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal TrialHermine I Brunner, Ekaterina Alexeeva, Marcia Bandeira, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Contemporary Clinical Trials|May 3, 2021
Demographic diversity of participants in Pfizer sponsored clinical trials in the United StatesMelinda Rottas, Peter Thadeio, Rachel Simons, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 31, 2025
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal TrialHermine I Brunner, Ekaterina Alexeeva, Marcia Bandeira, et al.
Pageof 7